{"slug":"tesamorelin-brain-fog","verification":{"valid":true,"entries":1,"head":"bf286df952897bbcddd46c0ea2f6cc573173ddc03b38e24c58e80351e9dfbbf1"},"count":1,"models":["grok/grok-4.3"],"yield":{"passes":1,"energy_spent_rows":0,"total_cost_usd":0.031806,"waste_cost_usd":0,"total_tokens":22252,"material_outputs":0,"usd_per_output":null,"models":[{"model":"grok/grok-4.3","passes":1,"cost_usd":0.031806,"tokens_total":22252,"outputs":0,"waste_passes":0,"usd_per_output":null}],"constraints":{"constitution":"/api/articles/constitution","collaborate_schema":"POST /api/protocol/collaborate","pricing_ppm":{"grok-4.3":[1.25,2.5],"grok/grok-4.3":[1.25,2.5],"grok-build-0.1":[1,2],"kimi/moonshot-v1-8k":[0.15,0.15],"gemini/gemini-2.5-flash":[0.075,0.3],"gemini/gemini-2.0-flash-lite":[0.075,0.3],"openai/gpt-4o":[2.5,10],"openai/gpt-4o-mini":[0.15,0.6],"system/reflex":[0,0],"ingest:deterministic":[0,0],"fill-slots":[0,0]}}},"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:27:13.207Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Tesamorelin for Statin-Associated Cognitive Effects: Human Trial Evidence on GH Axis and Cognition","register":"source_ledger","body":"## What's breaking down if you have Statin-associated cognitive effects\n\nStatin use is linked in some reports to reversible cognitive symptoms such as memory lapses, confusion, or brain fog. Large randomized trials and observational data have not shown consistent negative effects on cognition or dementia risk across populations. Proposed layers include possible statin impact on brain cholesterol synthesis in sensitive individuals, changes in myelin or neuronal membranes, or indirect effects through lowered LDL and raised glucose. These changes may tip the balance toward slower repair in neural tissue if breakdown outruns the brain's normal maintenance pathways. Visceral fat accumulation or reduced growth hormone signaling can compound age-related or metabolic stress on executive function and memory circuits. The result is a condition where cognitive symptoms persist until the underlying drivers of degeneration are addressed or natural repair processes are supported.\n\n## Why Tesamorelin might help you\n\nYou are reading about **Statin-associated cognitive effects** — what breaks down matters before any compound name.\n\n**Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\n\nIf your statin-related symptoms involve reduced growth hormone axis activity or excess visceral fat contributing to metabolic load on the brain, tesamorelin raises IGF-1 through stimulation of endogenous GH release. Higher physiological IGF-1 levels have been observed alongside improvements in executive function tasks such as response inhibition and set-shifting in older adults. If brain metabolite shifts like increased GABA support better inhibitory signaling in frontal regions, this may aid focus and reduce fog-like symptoms. If visceral fat reduction occurs, it may ease systemic inflammation that overlaps with cognitive strain. These steps follow from tesamorelin's documented action on the GH axis rather than direct symptom suppression.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **Tesamorelin** → GH axis / visceral fat\n\nTesamorelin addresses the GH axis and visceral fat layer. No other peptides are in scope here, so the article centers on how elevated IGF-1 and fat loss may intersect with statin-related cognitive layers without repeating mechanisms.\n\n## What the evidence actually shows\n\nHuman randomized controlled trial (Baker et al., 2012): 152 adults aged 55–87 (66 with mild cognitive impairment) received 1 mg daily tesamorelin or placebo for 20 weeks. Intent-to-treat analysis showed favorable effect on overall cognition (P = .03); completer analysis was more robust (P = .002). Executive function improved significantly (P = .005); verbal memory showed a trend (P = .08). IGF-1 rose 117% within normal range; body fat fell 7.4%. Visual memory was unaffected. This was a placebo-controlled human study in older adults, not statin users specifically.\n\nHuman substudy (Friedman et al., 2013): 30 participants from the above trial showed increased GABA across brain regions, increased NAAG in frontal cortex, and decreased myo-inositol in posterior cingulate after 20 weeks. Cognition effect replicated (P = .03). Correlated with IGF-1 changes in some metabolites. First direct evidence of GHRH modulating brain neurochemistry in humans.\n\nHuman trial in HIV (Ellis et al., 2025): 73 abdominally obese persons with HIV and neurocognitive impairment received tesamorelin or standard of care for 6 months (no placebo). Waist circumference dropped more with tesamorelin (median difference –2.7 cm, P = .015). Neurocognitive performance trended up in tesamorelin arm (mean change 0.146, P = .060) but not significantly different from standard care (P = .673). IGF-1 rose without correlation to cognitive scores. No clear between-group cognitive benefit shown; limited by power and design.\n\nNo human trials directly test tesamorelin in statin users with cognitive effects. Evidence tier: human for cognition improvements in MCI/healthy older adults; human for waist reduction in HIV obesity; mechanistic for brain metabolite changes.\n\n## What scientists say\n\nBaker et al. concluded 20 weeks of GHRH administration had favorable effects on cognition in both adults with MCI and healthy older adults. The 2013 metabolite paper noted this provides preliminary support for one possible mechanism explaining GHRH effects on cognition. Ellis et al. stated short-term adipose reduction with tesamorelin did not translate to significant neurocognitive improvement versus standard care in their cohort, highlighting study limitations.\n\n## What people say on Reddit\n\nPublic discussions on tesamorelin specifically for statin brain fog are sparse. Users researching peptides for cognitive support sometimes reference the Baker trial results when discussing GH axis compounds, but direct anecdotes tying tesamorelin to statin reversal are not prominent in searchable threads. General peptide forums note interest in tesamorelin for visceral fat but rarely link it to statin symptoms.\n\n## What people say on X\n\nLimited posts discuss tesamorelin in the context of cognitive function or statins. Mentions focus more on its approved use for HIV lipodystrophy or fat loss; occasional shares of the 2012 cognition study appear without personal statin-brain-fog experiences.\n\n## What we do not know\n\nNo data exist on tesamorelin specifically for statin-associated cognitive effects. It is unknown whether benefits seen in older or MCI populations translate to statin users. Long-term effects beyond 20 weeks on cognition, durability after stopping, or interaction with ongoing statin therapy remain unstudied. Correlation between IGF-1 changes and cognitive scores has not been consistent across trials. Mechanisms linking visceral fat reduction to brain fog relief in statin contexts are speculative.\n\n## Safety and limits\n\nHuman trials report mild adverse events more common with tesamorelin than placebo (68% vs 36% in one study). Common reports include injection site reactions and joint pain. IGF-1 stayed within physiological range in the cited trials. The 2025 HIV study noted no placebo arm and insufficient power for cognitive endpoints. All evidence is from specific populations (older adults, HIV); generalization to statin brain fog carries uncertainty. This article reviews published data only and does not constitute medical advice.","claims":[{"id":"c1","text":"Baker 2012 RCT (n=152 older adults, 20 weeks) showed tesamorelin improved executive function (P=0.005) and trended for verbal memory (P=0.08) vs placebo.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Direct human RCT evidence for cognitive effects of tesamorelin","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:27:12.828Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Ellis 2025 trial in HIV patients found tesamorelin reduced waist circumference (P=0.015) but no significant between-group cognitive benefit vs standard care.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Human data on tesamorelin in metabolic/neurocognitive context","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:27:12.828Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Friedman 2013 substudy showed tesamorelin increased brain GABA and altered metabolites alongside replicated cognitive benefit.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Human mechanistic data linking tesamorelin to brain changes","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:27:12.828Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"No randomized human trials test tesamorelin specifically in people with statin-associated cognitive effects.","section":"What we do not know","tier":"human","source_ids":[],"source_status":"unsourced","why_material":"Highlights evidence gap for the exact condition","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:27:12.828Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Statin cognitive effects are reported as rare, reversible, and not consistently confirmed in large RCTs or meta-analyses.","section":"What's breaking down if you have Statin-associated cognitive effects","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Frames the condition with actual human evidence level","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:27:12.828Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://jamanetwork.com/journals/jamaneurology/fullarticle/1306261","title":"Effects of Growth Hormone–Releasing Hormone on Cognitive Function in Adults With Mild Cognitive Impairment and Healthy Older Adults","quote":"Twenty weeks of GHRH administration had favorable effects on cognition in both adults with MCI and healthy older adults.","link_status":"http_403","quote_status":"unverified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39813152/","title":"Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity","quote":"While tesamorelin reduced WC, the cognitive benefits did not significantly differ between groups.","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/23689947/","title":"Growth hormone-releasing hormone effects on brain γ-aminobutyric acid and N-acetylaspartylglutamate","quote":"After 20 weeks of GHRH administration, GABA levels were increased in all brain regions (P < .04)... Consistent with the results of the parent trial, a favorable treatment effect on cognition was observed.","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"review","url":"https://www.lipid.org/lipid-spin/summer-2020/guest-editorial-statins-and-brain-fog-confusing-patients-prescribers-and-me","title":"Statins and Brain Fog: Confusing for Patients, Prescribers, and Me","quote":"Neurocognitive effects have been prospectively and retrospectively assessed in multiple statin trials and there is no signal of consistent effect.","link_status":"ok","quote_status":"verified"}]},"rationale":"","tokens_in":19059,"tokens_out":3193,"cost":0.03180625,"prev_hash":"genesis","hash":"bf286df952897bbcddd46c0ea2f6cc573173ddc03b38e24c58e80351e9dfbbf1"}]}